TG Therapeutics, Inc. $TGTX Stock Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA reduced its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 10.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,602,568 shares of the biopharmaceutical company’s stock after selling 183,383 shares during the quarter. Pictet Asset Management Holding SA owned about 1.05% of TG Therapeutics worth $89,391,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of TGTX. Ashton Thomas Private Wealth LLC acquired a new position in TG Therapeutics during the third quarter worth $497,000. Calamos Advisors LLC acquired a new stake in TG Therapeutics in the third quarter valued at $1,280,000. Kestra Advisory Services LLC boosted its position in shares of TG Therapeutics by 15.9% during the 3rd quarter. Kestra Advisory Services LLC now owns 4,610 shares of the biopharmaceutical company’s stock worth $257,000 after purchasing an additional 631 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its position in shares of TG Therapeutics by 6.3% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 31,862 shares of the biopharmaceutical company’s stock worth $1,777,000 after purchasing an additional 1,900 shares in the last quarter. Finally, First Nebraska Trust Co purchased a new stake in shares of TG Therapeutics during the 3rd quarter worth $390,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Stock Up 5.9%

TG Therapeutics stock opened at $63.38 on Tuesday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.72 and a current ratio of 4.27. The firm has a market capitalization of $9.70 billion, a price-to-earnings ratio of 23.13, a price-to-earnings-growth ratio of 2.60 and a beta of 1.89. TG Therapeutics, Inc. has a fifty-two week low of $26.76 and a fifty-two week high of $63.60. The stock’s fifty day moving average is $55.99 and its two-hundred day moving average is $44.66.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.02). TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%. The firm had revenue of $259.94 million for the quarter, compared to analyst estimates of $245.47 million. During the same period last year, the firm earned $2.43 EPS. The company’s quarterly revenue was up 60.8% compared to the same quarter last year. Analysts predict that TG Therapeutics, Inc. will post 0.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of TG Therapeutics stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $54.96, for a total transaction of $274,800.00. Following the completion of the transaction, the director owned 168,640 shares in the company, valued at approximately $9,268,454.40. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 8.87% of the company’s stock.

Wall Street Analysts Forecast Growth

TGTX has been the subject of a number of research analyst reports. Zacks Research upgraded shares of TG Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 4th. JPMorgan Chase & Co. boosted their price objective on shares of TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. HC Wainwright restated a “buy” rating and set a $78.00 target price on shares of TG Therapeutics in a research report on Tuesday, September 1st. B. Riley Financial increased their target price on shares of TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a report on Monday, July 27th. Finally, Weiss Ratings raised shares of TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $63.00.

Key Stories Impacting TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Third-quarter revenue was $259.9 million, up 60.8% year over year and above estimates of about $245.5 million. TG Therapeutics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its 2026 revenue outlook to $1.0 billion, ahead of the roughly $961 million consensus. CEO Michael Weiss also said global revenue could exceed $1 billion, with BRIUMVI driving growth. TG Therapeutics CEO sees global revenue exceeding $1B in 2026
• Neutral Sentiment: EPS was $0.35. That topped Zacks’ $0.28 estimate, but was below other reported consensus figures around $0.37; earnings were also lower than the $2.43 reported a year earlier. TG Therapeutics beats Q3 earnings and revenue estimates

TG Therapeutics Company Profile

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions.

The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Headquartered in New York, TG Therapeutics serves patients in the United States and has expanded BRIUMVI’s availability into international markets, including Europe.